NCT04971733 2025-06-10
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
Eisai Inc.
Phase 1/2 Completed
Eisai Inc.
Janssen Research & Development, LLC
Alzinova AB
Prothena Biosciences Ltd.
GlaxoSmithKline
Eisai Inc.
GlaxoSmithKline
Novartis